Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Status:
Completed
Trial end date:
2012-03-07
Target enrollment:
Participant gender:
Summary
This study will compare the safety and efficacy of dalotuzumab (MK-0646) in combination with
cetuximab and irinotecan in treating participants with wild type KRAS (wtKRAS) metastatic
colorectal cancer (CRC) compared to cetuximab and irinotecan alone.
The primary study hypothesis is that administration of dalotuzumab in combination with
cetuximab and irinotecan to participants with metastatic CRC expressing the wtKRAS genotype
improves Overall Survival OR Progression-free Survival compared to participants treated with
cetuximab and irinotecan alone.